Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
20.57
+0.42 (2.08%)
Feb 6, 2026, 12:47 PM EST - Market open
Syndax Pharmaceuticals Revenue
Syndax Pharmaceuticals had revenue of $45.87M in the quarter ending September 30, 2025, with 266.97% growth. This brings the company's revenue in the last twelve months to $111.55M, up 597.19% year-over-year. In the year 2024, Syndax Pharmaceuticals had annual revenue of $23.68M.
Revenue (ttm)
$111.55M
Revenue Growth
+597.19%
P/S Ratio
15.67
Revenue / Employee
$412,237
Employees
270
Market Cap
1.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.68M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 139.71M | 138.19M | 9,109.56% |
| Dec 31, 2020 | 1.52M | - | - |
| Dec 31, 2019 | 1.52M | - | - |
| Dec 31, 2018 | 1.52M | -591.00K | -28.04% |
| Dec 31, 2017 | 2.11M | 888.00K | 72.79% |
| Dec 31, 2016 | 1.22M | 593.00K | 94.58% |
| Dec 31, 2015 | 627.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.41B |
| Ardelyx | 398.23M |
| MannKind | 313.79M |
| Vericel | 258.72M |
| Stoke Therapeutics | 205.63M |
| Zymeworks | 134.48M |
| Nurix Therapeutics | 83.98M |
| Recursion Pharmaceuticals | 43.69M |
SNDX News
- 1 day ago - Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit - GlobeNewsWire
- 1 day ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 24 days ago - Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 25 days ago - Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S. - GlobeNewsWire
- 4 weeks ago - Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Syndax Pharma: Continuing Execution In AML - Seeking Alpha
- 2 months ago - Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025 - GlobeNewsWire